Alan Lacy - Bristol Myers Independent Director

Director

Mr. Alan J. Lacy is Independent Director of BristolMyers Squibb Company. Mr. Lacy served as the NonExecutive Chairman of Dave Buster Entertainment Inc. from 2014 to 2017. He served as the Chairman and Chief Executive Officer of Sears, Roebuck and Co. and the Vice Chairman and Chief Executive Officer of its successor, Sears Holdings Corporationrationration, from 2000 to 2005. Mr. Lacy also served as Vice Chairman of Sears Holdings Corporation from 2005 to 2006. More recently, Mr. Lacy served as Senior Advisor to Oak Hill Capital Partners, L.P., a private equity investment firm, from 2007 to 2014. He is a Trustee of Fidelity Funds and the California Chapter of The Nature Conservancy. Mr. Lacy is a Director of the Center for Advanced Study in the Behavioral Sciences at Stanford University. since 2008.
Age 64
Tenure 16 years
Phone212-546-4000
Webhttp://www.bms.com

Similar Executives

Showing other executives

DIRECTOR Age

Greg OGormanRyanair Holdings PLC
N/A
Mike OBrienRyanair Holdings PLC
73
Julie ONeillRyanair Holdings PLC
62
Lisbeth McNabbNexstar Broadcasting Group
57
Dennis FitzSimonsNexstar Broadcasting Group
67
Robert ShortVirnetX Holding Corp
68
James OsborneRyanair Holdings PLC
67
Declan McKeonRyanair Holdings PLC
66
Martin PompadurNexstar Broadcasting Group
82
Kyran McLaughlinRyanair Holdings PLC
73
Jay GrossmanNexstar Broadcasting Group
58
Roisin BrennanRyanair Holdings PLC
53
Gary FeinerVirnetX Holding Corp
57
Edward WilsonRyanair Holdings PLC
53
John LeahyRyanair Holdings PLC
N/A
Charles McCreevyRyanair Holdings PLC
67
Thomas McMillenNexstar Broadcasting Group
65
Michael HorganRyanair Holdings PLC
77
Michael AngeloVirnetX Holding Corp
60
Emer DalyRyanair Holdings PLC
54
Stan McCarthyRyanair Holdings PLC
59
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug Manufacturers - Major classification in USA and is traded on OTC Market. It employs 23700 people. Bristol Myers Squibb [BMYMP] is a Pink Sheet which is traded between brokers over the counter.

Bristol-Myers Squibb Leadership Team

Elected by the shareholders, the Bristol Myers' board of directors comprises two types of representatives: Bristol Myers inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bristol. The board's role is to monitor Bristol Myers' management team and ensure that shareholders' interests are well served. Bristol Myers' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bristol Myers' outside directors are responsible for providing unbiased perspectives on the board's policies.
Ann Powell, Chief Human Resource Officer, Senior Vice President
Togo West, Independent Director
Karen Vousden, Director
Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics Officer
Alan Lacy, Independent Director
Robert Bertolini, Independent Director
Jose Baselga, Independent Director
Charles Bancroft, CFO, Executive Vice President
Gerald Storch, Independent Director
Louis Schmukler, President - Global Manufacturing and Supply
Michael Grobstein, Independent Director
Christopher Boerner, Executive Vice President and Chief Commercial Officer
John Elicker, Senior Vice President - Public Affairs and Investor Relations
Anne Nielsen, Senior Vice President Chief Compliance and Ethics Officer
Karen Santiago, Senior Vice President Controller
Giovanni Caforio, COO, Director
Vicki Sato, Independent Director
Emmanuel Blin, Senior Vice President Chief Strategy Officer
Joseph Caldarella, Senior Vice President Corporate Controller
Laurie Glimcher, Independent Director
Murdo Gordon, Executive Vice President Chief Commercial Officer
Lamberto Andreotti, CEO, Director
Thomas Lynch, Independent Director
Dinesh Paliwal, Independent Director
Lewis Campbell, Independent Director
Theodore Samuels, Independent Director
Samuel Moed, Senior Vice President - Strategic Planning and Analysis
Matthew Emmens, Independent Director
Ann Judge, Senior Vice President - Global Human Resources
Sandra Leung, General Counsel, Corporate Secretary
Paul Autenried, Senior Vice President - Enterprise Services, CIO
Francis Cuss, Executive Vice President Chief Scientific Officer
Paul Biondi, Senior Vice President Head - Business Development
Peter Arduini, Independent Director

Bristol Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bristol Myers a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bristol Myers in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bristol Myers' short interest history, or implied volatility extrapolated from Bristol Myers options trading.

Pair Trading with Bristol Myers

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to PGE Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace PGE Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back PGE Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling PGE Corp to buy it.
The correlation of PGE Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as PGE Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if PGE Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for PGE Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Other Consideration for investing in Bristol Pink Sheet

If you are still planning to invest in Bristol-Myers Squibb check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bristol Myers' history and understand the potential risks before investing.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.